What is the 13F Pro Quality Score for RPRX?

13F Pro ranks Royalty Pharma plc (RPRX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View RPRX's current score at https://13fpro.ai/research/RPRX (free sign-up required for the full ranking).

Which hedge funds own the most RPRX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of RPRX include MORGAN STANLEY, Capital International Investors, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/RPRX as soon as new 13F filings post.

Where does 13F Pro source RPRX data?

All Royalty Pharma plc fundamentals and ownership data come directly from SEC EDGAR. Royalty Pharma plc files with the SEC under CIK 1802768. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is RPRX in?

Royalty Pharma plc (RPRX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is RPRX research updated on 13F Pro?

RPRX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Royalty Pharma plc(RPRX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1802768 RPRX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

RPRX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Royalty Pharma plc (RPRX), a Healthcare sector company. RPRX is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Royalty Pharma plc reports quarterly revenue of $630.6M, net income of $294.7M, free cash flow of $718.2M. Top institutional holders of RPRX by reported 13-F value include MORGAN STANLEY, Capital International Investors, BlackRock,, based on the most recent SEC filings. RPRX trades on the Nasdaq exchange and files with the SEC under CIK 1802768. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RPRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Royalty Pharma plc directly from SEC EDGAR.

Revenue

Q1 2026

$630.6M

Net Income

Q1 2026

$294.7M

Free Cash Flow

Q1 2026

$718.2M

ROIC

Q1 2026

3.0%

D/E Ratio

Q1 2026

0.94

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+5.1% YoY

$2.38BFY 2025

FY22 $2.24BFY23 $2.35BFY24 $2.26BFY25 $2.38B

Net Income

-10.2% YoY

$770.9MFY 2025

FY22 $42.8MFY23 $1.13BFY24 $859.0MFY25 $770.9M

Operating Income

+20.7% YoY

$1.56BFY 2025

FY22 $307.1MFY23 $1.49BFY24 $1.29BFY25 $1.56B

EPS (Diluted)

-6.8% YoY

$1.78FY 2025

FY22 $0.10FY23 $2.53FY24 $1.91FY25 $1.78

Total Assets

+7.7% YoY

$19.62BFY 2025

FY22 $16.81BFY23 $16.38BFY24 $18.22BFY25 $19.62B

Total Debt

+8.4% YoY

$9.33BFY 2025

FY22 $8.11BFY23 $6.14BFY24 $8.61BFY25 $9.33B

Op. Cash Flow

-10.1% YoY

$2.49BFY 2025

FY22 $2.14BFY23 $2.99BFY24 $2.77BFY25 $2.49B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$2.38B +5.1%	$2.26B -3.9%	$2.35B +5.2%	$2.24B -2.3%	$2.29B +7.9%	$2.12B
Net Income	$770.9M -10.2%	$859.0M -24.3%	$1.13B +2549.5%	$42.8M -93.1%	$619.7M -36.4%	$975.0M
Operating Income	$1.56B +20.7%	$1.29B -13.4%	$1.49B +385.9%	$307.1M -78.5%	$1.43B -10.3%	$1.60B
EPS (Diluted)	$1.78 -6.8%	$1.91 -24.5%	$2.53 +2430.0%	$0.10 -93.3%	$1.49 +12.9%	$1.32
Total Assets	$19.62B +7.7%	$18.22B +11.2%	$16.38B -2.6%	$16.81B -4.0%	$17.52B +9.3%	$16.02B
Total Debt	$9.33B +8.4%	$8.61B +40.3%	$6.14B -24.4%	$8.11B +14.3%	$7.10B +22.0%	$5.82B
Operating Cash Flow	$2.49B -10.1%	$2.77B -7.3%	$2.99B +39.4%	$2.14B +6.3%	$2.02B -0.8%	$2.03B

AI Insight: RPRX Ratio Trends

RPRX margins are highly volatile quarter-to-quarter, but Q1 2026 shows a strong rebound with ROIC recovering to 24.1% after Q2 2025's sharp trough.

• ROIC swung from 9.3% in Q2 2025 to 24.1% in Q1 2026, reflecting significant quarter-to-quarter earnings volatility rather than a smooth trend.

• Operating margin in Q1 2026 reached 89.3%, up sharply from Q2 2025's 36.3% trough, though still below Q3 2024's anomalous 130.2%.

• TTM ROA of 4.2% and ROIC of 17.0% sit below the Q1 2026 quarterly-annualized figures, suggesting recent momentum above the trailing average.

⚠ Q2 2025 NPM collapsed to 5.2% from 41.9% the prior quarter — identifying the driver of that one-off compression is critical for forward visibility.

⚠ ROE is unavailable across all periods; without it, equity-return efficiency and leverage impact on shareholder returns remain unquantifiable.

⚠ D/E data is absent entirely — RPRX's royalty acquisition model relies on debt funding, making leverage trajectory a key unmonitored risk here.

Get alerted when RPRX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Royalty Pharma plc including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of RPRX

MORGAN STANLEY
$2.1B43,571,633 sh
Capital International Investors
$1.7B35,005,736 sh
BlackRock, Inc.
$1.2B25,907,745 sh
FMR LLC
$1.2B25,152,242 sh
BAILLIE GIFFORD & CO
$775.0M16,155,677 sh
Swedbank AB
$555.8M11,586,693 sh
STATE STREET CORP
$527.2M10,989,851 sh
Capital World Investors
$385.5M8,036,714 sh
GEODE CAPITAL MANAGEMENT, LLC
$376.5M7,869,632 sh
ADAGE CAPITAL PARTNERS GP, L.L.C.
$358.8M7,480,633 sh

Fund	Value	Shares
MORGAN STANLEY	$2.1B	43,571,633
Capital International Investors	$1.7B	35,005,736
BlackRock, Inc.	$1.2B	25,907,745
FMR LLC	$1.2B	25,152,242
BAILLIE GIFFORD & CO	$775.0M	16,155,677
Swedbank AB	$555.8M	11,586,693
STATE STREET CORP	$527.2M	10,989,851
Capital World Investors	$385.5M	8,036,714
GEODE CAPITAL MANAGEMENT, LLC	$376.5M	7,869,632
ADAGE CAPITAL PARTNERS GP, L.L.C.	$358.8M	7,480,633

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put RPRX on your watchlist

Track score changes the day Royalty Pharma plc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is RPRX a good stock to buy?

13F Pro's AI-powered analysis of Royalty Pharma plc (RPRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RPRX are available on the RPRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own RPRX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RPRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Royalty Pharma plc's investment landscape.